Regenxbio reported positive interim safety and efficacy data for RGX-202 in the Phase I/II Affinity Duchenne trial, showing promising results for patients with Duchenne muscular dystrophy aged 1 to 11.
PPMD's EHR Study will extract data from Certified Duchenne Care Centers to collect clinical data to inform research and care.
The CureDuchenne Occupational Therapist Certification Program provides advanced training to help OTs deliver specialized care.
MD and IAFF kick off more than 250 Fill the Boot events to raise lifesaving funds throughout Labor Day weekend in over 25 states.
Read More
Cure Rare Disease announces the approval from the U.S. Food and Drug Administration to administer its very first therapeutic.
Read More
Parent Project Muscular Dystrophy expands their Certified Duchenne Care Center Program with the certification of the Billings Clinic.
Read More
The Oxford-Harrington Rare Disease Centre announce its support of a novel treatment for Duchenne muscular dystrophy.
Read More
Sarepta Therapeutics Inc announces its intent to submit a BLA seeking accelerated approval for SRP-9001 to treat individuals with Duchenne.
Read More
CIONIC announces a collaboration with acclaimed designer Yves Behar and his world-renowned multidisciplinary design firm, fuseproject.
Read More
Parent Project Muscular Dystrophy adds the clinic at UPMC Children’s Hospital of Pittsburgh to its Certified Duchenne Care Center Program.
Read More
Fulcrum Therapeutics is using AMRA Medical’s muscle fat infiltration (MFI) as a secondary endpoint in its phase 3 FSHD clinical trial: REACH.
Read More
Parent Project Muscular Dystrophy expands its Certified Duchenne Care Program with the certification of the first clinic in St. Louis.
Read More
Mutations that cause Duchenne muscular dystrophy slow electrical activity in the heart, causing abnormal heart rhythms, a study notes.
Read More
AMRA Medical publishes results of its Fulcrum-sponsored study highlighting the development and use of a MRI protocol for muscle analysis.
Read More
Parent Project Muscular Dystrophy nominates Duchenne to be part of Recommended Uniform Screening Panel (RUSP) for newborns.
Read More
ICD-10-CM codes for LGMD and several of its subtypes will be fully implemented and ready for use starting this October, MDA reports.
Read More
An existing cancer drug could have potential as a treatment for muscular dystrophy, researchers suggest in a new study.
Read More
Parent Project Muscular Dystrophy will host its 2022 Annual Conference in Scottsdale, Arizona, June 23-26.
Read More